Q3 2025 Akebia Therapeutics Inc Earnings Call Transcript
Key Points
- Akebia Therapeutics Inc (AKBA) reported a significant increase in total revenues, reaching $58.8 million in Q3 2025, up from $37.4 million in the same quarter last year.
- The company successfully increased accessible patients from 40,000 in the first half of the year to almost 70,000 by the end of Q3, thanks to the initiation of the DaVita pilot and the addition of IRC and several smaller providers.
- Vasio has generated more total prescriptions in its first 41 weeks of launch than any recent launch in dialysis, indicating strong reception from the dialysis community.
- The company presented promising data at the American Society of Nephrology meeting, showing that Vasio could potentially lower the risk of death or hospitalization compared to ESA control.
- Akebia Therapeutics Inc (AKBA) ended Q3 with a strong cash position of $166.4 million, which is expected to fund current operating plans to profitability.
- Despite the increase in prescriptions, Akebia Therapeutics Inc (AKBA) reported only $14.3 million in revenue from Vasio this quarter, which was below expectations.
- The company is facing operational challenges in aligning logistics and processes for the new therapy, particularly in the highly protocolized dialysis environment.
- Adherence rates at US Renal Care (USRC) were lower than expected, impacting the overall growth and requiring retraining of the sales team and adjustments in protocols.
- The transition to TIW dosing and the shift from 150 mg to 300 mg tablets at USRC could impact inventory levels and patient starts in Q4.
- There is uncertainty around the timing of potential additional generic competition for Oryxia, which could affect future sales levels.
Good day and thank you for standing by. Welcome to Akivia's 3rd quarter 2025 financial results conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Mercedes Carrasco, senior Director of Investor relations. Please go ahead.
Thank you and welcome to Keia's 3rd quarter 2025 financial results and business updates conference call. Please note that a press release was issued earlier today, Monday, November 10th, detailing our 3rd quarter 2025 financial results, and that release is available on the investors section of our website. For your convenience, a replay
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
